Rt Hon JACINDA ARDERN: Of course, the member knows that we ran a programme of accessing or seeking supply and purchase arrangements with more than one pharmaceutical company and more than one vaccine. I think it's easy to forget that, actually, last year, many countries were purchasing vaccines before they'd even completed clinical trials, and we were in that position too. So our approach was to seek vaccines that were across different technologies, and, therefore, one, for instance, RNA vaccine; one of a more traditional variety that led to us seeking Janssen, Novavax, Pfizer, and AstraZeneca. We then made a decision later on in the campaign that our view was that purchasing for the totality of our population with one option was the best way to go for our delivery campaign. We have that with Pfizer—over 10 million doses, the bulk of those being delivered in October. The biggest difference, though, between us and many other countries is that they started rolling out their vaccines under emergency approvals, rather than full approvals. Our focus was ensuring that we had the confidence of New Zealanders, so we used a full Medsafe approval. That, alongside supply, explains some of the differences in the roll-outs between different countries.